MannKind Reports Q1 Revenue of $90.17M, Below Consensus
Reports Q1 revenue $90.17M, consensus $105.31M. "We are making meaningful progress executing our corporate transformation strategy, focused on the expansion and diversification of both our commercial portfolio and development pipeline," said Michael Castagna, Chief Executive Officer of MannKind Corporation. "2026 is the most catalyst-rich year in the Company's history. The Furoscix ReadyFlow Autoinjector, if approved, represents an opportunity to scale the brand's growth trajectory. At the same time, we are excited and prepared for the potential Afrezza approval and launch in pediatrics, which would address unmet needs of a new patient population. Combined with the continued momentum of Tyvaso DPI, including its expansion into IPF, a strengthening pipeline, and our expanded collaboration with United Therapeutics to advance ralinepag DPI, MannKind is well positioned to deliver sustained, long-term value for shareholders."
